Table 3.
Relative abundance of CB1 and CB2 cannabinoid receptors and FAAH in specific cell subpopulations in active and chronic MS lesions
| Active lesions |
Chronic lesions |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HLA-DR | CD68 | GFAP | PDGFR-α | MBP | CD3 | MAP-2 | HLA-DR | CD68 | GFAP | PDGFR-α | MBP | CD3 | MAP-2 | |
| CB1 | ++ | ++ | ND | + | + | ++ | ++ | ND | ND | ND | ND | ND | ++ | ++ |
| CB2 | ++++ | ++++ | + | ND | ND | ++ | ND | ++++ | ND | ND | ND | ND | ++ | ND |
| FAAH | ND | ND | +++ | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
Data shown are the number of positive cells for two markers in at least three sections per case. +, <10 cells/tissue section; ++, 10–25 cells/tissue section; +++, 25–50 cells/tissue section; ++++, >50 cells/tissue section; ND, nondetectable.